Cartalax

CARTALAX | 20MG

SHORT-PEPTIDE BIOREGULATOR  •  CONNECTIVE-TISSUE RESEARCH

Explore the science of cellular resilience and cartilage-associated signaling.

Cartalax is a synthetic three-amino-acid peptide (Ala–Glu–Asp, or AED) associated with the Khavinson short-peptide bioregulator research program. Investigators have examined AED in laboratory models of cellular aging, connective-tissue biology, and cartilage-related differentiation. This compact research peptide offers a focused way to investigate how specific gene-expression patterns change as cells age.

The Science Behind Cartalax

Cartalax has been studied primarily in cell cultures—not in controlled human clinical trials. The clearest cartilage-related findings involve markers associated with chondrogenic differentiation and tissue-matrix biology, rather than demonstrated restoration of damaged cartilage.

Cartilage-Associated Gene Expression

In a 2023 in-vitro study using aging human mesenchymal stem cells, researchers reported increased expression or synthesis of SOX9, aggrecan, type II collagen, and cartilage oligomeric matrix protein (COMP) following exposure to AED. These markers are important to the study of cartilage-cell differentiation, but marker changes alone do not establish functional cartilage repair.

Cellular Aging and Matrix Research

Other experiments involving chondrocytes, fibroblasts, and additional cell models have explored senescence-related signaling, proliferation-associated proteins, and matrix-regulating enzymes. Reported changes are preliminary and may depend on the tissue model, experimental conditions, and measured endpoint.

Key Research Areas

• Chondrogenic differentiation:  Study of signaling and molecular markers associated with cartilage-forming cells.

• Extracellular matrix biology:  Exploration of proteins relevant to cartilage structure and connective-tissue maintenance.

• Cellular senescence:  Investigation of age-associated changes in cell signaling and stress-response markers.

• Short-peptide bioregulation:  Evaluation of gene-expression responses to an ultrashort synthetic peptide.

• Comparative tissue models:  Research spanning mesenchymal stem cells, chondrocytes, and fibroblast cultures.

  
  

RESTORE WHAT WAS ALWAYS THERE.

A Focused Platform for Discovery

Biological aging is shaped by intricate interactions between cellular communication, extracellular-matrix dynamics, and the capacity of tissues to respond to changing conditions. Cartalax brings a minimalist molecular structure to this evolving field of research: three amino acids and a growing body of exploratory laboratory findings.

For investigators examining chondrogenesis, senescence-linked markers, and peptide-associated gene expression, AED is an interesting research subject. The central question remains whether early observations in isolated cells can be reproduced independently and translated into meaningful effects in living organisms.

Origin.1 Philosophy

At Origin.1, we believe meaningful scientific progress begins with curiosity and disciplined investigation. Our research catalog highlights compounds of interest for understanding the body’s signaling networks, cellular adaptation, and biological complexity.

Origin.1 — Build. Adapt. Become.

Product Specifications

Research Status & Important Limitations

The available evidence for AED is predominantly preclinical and concentrated among a small number of related research groups. In-vitro findings should not be interpreted as proof that Cartalax relieves joint pain, regenerates cartilage, reverses arthritis, or produces clinical benefits in humans. Human safety, pharmacokinetics, optimal dosing, and therapeutic effectiveness have not been established.

RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION.

Cartalax is not an FDA-approved drug. No statements in this document are intended to diagnose, treat, cure, or prevent disease. Identity, content, purity, and physical form should be verified against product-specific analytical documentation.